Bruker Co. (NASDAQ:BRKR) Receives Consensus Recommendation of “Buy” from Analysts
Bruker Co. (NASDAQ:BRKR) has received an average rating of “Buy” from the fifteen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $49.20.
A number of research analysts recently weighed in on BRKR shares. BidaskClub lowered shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine raised shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, August 31st. Bank of America reaffirmed a “neutral” rating and issued a $52.00 price target (up from $44.00) on shares of Bruker in a research note on Friday, June 21st. Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and raised their price target for the company from $32.00 to $48.00 in a research note on Monday, July 15th. Finally, Jefferies Financial Group raised their price target on shares of Bruker from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, June 21st.
In other Bruker news, CEO Burkhard Prause sold 15,702 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $42.96, for a total value of $674,557.92. Following the transaction, the chief executive officer now directly owns 1,338 shares of the company’s stock, valued at approximately $57,480.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 26.50% of the company’s stock.
Shares of NASDAQ:BRKR traded down $0.80 during trading on Thursday, reaching $43.68. 59,080 shares of the company’s stock traded hands, compared to its average volume of 799,206. Bruker has a fifty-two week low of $26.10 and a fifty-two week high of $51.41. The company has a quick ratio of 1.27, a current ratio of 2.19 and a debt-to-equity ratio of 0.63. The firm has a market cap of $6.59 billion, a PE ratio of 31.20, a P/E/G ratio of 2.10 and a beta of 1.41. The company has a 50-day simple moving average of $43.07 and a 200-day simple moving average of $42.58.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, August 1st. The medical research company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The firm had revenue of $490.20 million for the quarter, compared to analysts’ expectations of $477.70 million. Bruker had a return on equity of 27.10% and a net margin of 9.57%. The company’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $0.25 EPS. On average, equities research analysts forecast that Bruker will post 1.61 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Tuesday, September 3rd will be paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Friday, August 30th. Bruker’s dividend payout ratio (DPR) is 11.43%.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.